Baxter International Inc. announced the completion of its planned acquisition of Baxa Corporation, a privately held global company based in Englewood, Colo., for a cash consideration of $380 million. Baxa develops pharmacy technology that enhances the efficiency and safety of oral and IV dose preparation and delivery.

“The acquisition of Baxa demonstrates Baxter’s long-term commitment to nutrition and patient safety and it allows us to offer a broader range of solutions for the safe preparation and delivery of IV medications,” says Robert M. Davis, president of Baxter’s Medical Products business. “We believe Baxa’s expertise in safely preparing IV and oral liquid medications, and their shared commitment toward improving patient care through innovative drug preparation and delivery technology will benefit patients around the world.”

Among the product offerings now part of the Baxter portfolio are the ExactaMix Compounder, devices that automate multi-ingredient solution compounding; ExactaMed Syringes, dispensers that provide greater accuracy for dosing oral liquid medications; NeoThrive
Enteral Feeding System, enteral syringes and accessories; and the DoseEdge Pharmacy Workflow Manager, an integrated system for managing IV and oral dose preparation activities.

Annual sales for Baxa were $157 million in 2010, and Baxter expects the top-line growth of this business to be accretive to the company’s future sales growth. In addition, Baxter expects this transaction to be dilutive to 2012 earnings by $0.03 to $0.05 per diluted share primarily related to acquisition-accounting and transaction-related expenses. Excluding these items, the acquisition is neutral to full-year 2012 earnings and increasingly accretive thereafter.

Release date: Nov. 10, 2012
Source: Baxter International